Literature DB >> 402317

Membrane associated antigens of human malignant melanoma. III. Specificity of human sera reacting with cultured melanoma cells.

E Seibert, C Sorg, R Happle, E Macher.   

Abstract

Sera from melanoma patients, healthy donors, pregnant women and patients with types of tumors other than melanoma were tested on various melanoma lines as well as on a cultured brain tumor and adult skin fibroblasts, using a microimmune adherence test. Positive reactions against all cell lines were found in serum from each group of donors. The degree of reactivity was dependent on the cell line used. Sequential absorption with AB Rh+ and pooled platelets of more than 200 donors either reduced the titer of sera or rendered a great part of the sera negative, demonstrating that antibodies against HL-A antigens and other tissue antigens were involved. The remaining positive sera were further absorbed with pooled cells from 6- to 8-week-old fetuses. This step abolished the reactivity of most sera, indicating the relatively high frequency of antibodies in males and females against fetal antigens expressed also on melanoma and other cells. In order to determine the specificity of the few remaining positive sera, absorptions with three different melanoma cell lines, a brain tumor and fibroblasts were carried out. The results showed only partial cross-reactivity between different cell lines. No evidence was obtained from this study for the existence of a common cross-reacting membrane-associated antigen on human malignant melanoma. Antigens that could be readily detected seemed mostly to be tumor-associated fetal antigens.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402317     DOI: 10.1002/ijc.2910190206

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Tumor vaccines.

Authors:  J C Bystryn
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

2.  Human malignant melanoma antigenic properties of phenol water extracts.

Authors:  L Suter; H Tilkorn; P M Kövary
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

3.  [Immunology of malignant melanoma (author's transl)].

Authors:  E Macher; C Sorg; E r Seibert
Journal:  Langenbecks Arch Chir       Date:  1976-11-15

4.  Reaction of the leukocytes of melanoma patients and control donors, including pregnant women, with melanoma- and fetus-derived materials.

Authors:  A J Cochran; G Todd; D M Hart; L J Morrison; R M MacKie
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Comparative histological studies of regional lymph nodes of 201 melanoma patients. (Microscopic features in relation to individual age, site, and metastatic spread).

Authors:  F Weidner
Journal:  Arch Dermatol Res       Date:  1979-10       Impact factor: 3.017

6.  Studies of cellular mediated immunity in malignant melanoma patients by Leukocyte Adherence Inhibition Test.

Authors:  S Müller; T M Ernst
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

7.  Tumor production in the nude mouse, fibrinolytic activity and cross-reactivity with antimelanoma sera of various human tumor cell lines.

Authors:  J Brüggen; J Fogh; C Sorg
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

8.  Detection of a low-molecular-weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assays.

Authors:  P Hersey; E Murray; J Werkmeister; W H McCarthy
Journal:  Br J Cancer       Date:  1979-10       Impact factor: 7.640

9.  Analysis of heteroantisera to cells from human malignant effusions by immunofluorescence and protein A binding.

Authors:  J P Birchall; J J Owen; B S Owen
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.